|
|
Letter
Fluoroquinolone-resistant
Salmonella sp. in Carcasses
Yu-Chih Wang,* Kuang-Sheng Yeh,† Chao-Chin Chang,* Shih-Ling Hsuan,*
and Ter-Hsin Chen*
*National Chung Hsing University, Taichung, Taiwan; and †Taipei Medical
University, Taipei, Taiwan
Suggested
citation for this article
To the Editor: Fluoroquinolone (FQ)-resistant Salmonella
has been isolated from patients in Taiwan (1–7).
Recently, a report further indicated that several patients were infected
with Salmonella enterica serovar Schwarzengrund with high-level
FQ resistance (1). S. Schwarzengrund has
never been isolated from food animals in Taiwan.
We report the isolation of FQ-resistant strains from pork and broiler
carcasses sampled from 2000 to 2003: 27 in 2000, 3 in 2001, 4 in 2002,
and 2 in 2003. These isolates made up 18.85% of the 191 Salmonella
strains obtained from pork and broiler carcasses in the study period.
Of these isolates, 16 FQ-resistant S. Schwarzengrund strains were
further analyzed to elucidate the possible mechanism of FQ resistance.
Ciprofloxacin MIC levels in these isolates ranged from 4 to 16 μg/mL,
and all had high-level nalidixic acid resistance (>1,024 μg/mL).
All of the 16 investigated strains displayed mutations possibly associated
with high-level FQ resistance. The mutation sites included 2 sites (Ser83Phe
and Asp87Gly) in the quinolone resistance–determining region (QRDR) of
gyrA, 2 sites (Thr57Ser and Ser80Arg) in the QRDR of parC,
and 1 site (Ser458Pro) in the QRDR of parE, respectively. Four
strains had mutations in the QRDR of gyrA and parC only
but not in the QRDR of parE (Table).
In conclusion, high-level FQ resistance was detected in S. Schwarzengrund
isolated from pork and chicken in Taiwan. Specific mutation sites of gyrA,
parC, and parE were associated with high-level FQ resistance
in all the isolates investigated. Our results warrant further investigation
of the public health consequences of FQ use in food animals in Taiwan.
References
- Baucheron S, Chaslus-Dancla E, Cloeckaert A, Chiu
CH, Butaye P. High-level
resistance to fluoroquinolones linked to mutations in gyrA, parC,
and parE in Salmonella enterica serovar Schwarzengrund
isolates from humans in Taiwan. Antimicrob Agents Chemother. 2005;49:862–3.
- Chiu CH, Su LH, Hung CC, Chen KL, Chu C. Prevalence
and antimicrobial susceptibility of serogroup D nontyphoidal Salmonella
in a university hospital in Taiwan. J Clin Microbiol. 2004;42:415–7.
- Chiu CH, Wu TL, Su LH, Chu C, Chia JH, Kuo AJ, et al. The
emergence in Taiwan of fluoroquinolone resistance in Salmonella enterica
serotype Choleraesuis. N Engl J Med. 2002;346:413–9.
- Chiu CH, Wu TL, Su LH, Liu JW, Chu C. Fluoroquinolone
resistance in Salmonella enterica serotype Choleraesuis, Taiwan,
2000–2003. Emerg Infect Dis. 2004;10:1674–6.
- Hsueh PR, Teng LJ, Tseng SP, Chang CF, Wan JH, Yan JJ, et al. Ciprofloxacin-resistant
Salmonella enterica Typhimurium and Choleraesuis from pigs to
humans, Taiwan. Emerg Infect Dis. 2004;10:60–8.
- Huang TM, Chang YF, Chang CF. Detection
of mutations in the gyrA gene and class I integron from quinolone-resistant
Salmonella enterica serovar Choleraesuis isolates in Taiwan.
Vet Microbiol. 2004;100:247–54.
- Ko WC, Yan JJ, Yu WL, Lee HC, Lee NY, Wang LR, et al. A
new therapeutic challenge for old pathogens: community-acquired invasive
infections caused by ceftriaxone- and ciprofloxacin-resistant Salmonella
enterica serotype Choleraesuis. Clin Infect Dis. 2005;40:315–8.
Table. Characteristics
of ciprofloxacin-resistant Salmonella enterica serovar Schwarzengrund
strains from carcasses*†
|
|
Strain no.
|
Origin*
|
Year isolated
|
Antimicrobial drug resistance profile
|
Quinolone MICs (μg/mL)
|
Substitutions in QRDR‡
|
|
|
NAL
|
FLU
|
ENR
|
CIP
|
gyrA
|
parC
|
parE
|
|
A5
|
B, M
|
2000
|
CmSxtTc
|
1,024
|
512
|
32
|
8
|
Ser83Phe;
Asp87Gly
|
Thr57Ser;
Ser80Arg
|
Ser458Pro
|
A16
|
P, E
|
2000
|
ApCmNSxtTc
|
2,048
|
512
|
32
|
8
|
Ser83Phe;
Asp87Gly
|
Thr57Ser;
Ser80Arg
|
Ser458Pro
|
A17
|
P, E
|
2000
|
ApCmNSxtTc
|
2,048
|
512
|
32
|
16
|
Ser83Phe;
Asp87Gly
|
Thr57Ser;
Ser80Arg
|
Ser458Pro
|
A18
|
P, E
|
2000
|
ApCmNSxtTc
|
2,048
|
512
|
32
|
16
|
Ser83Phe;
Asp87Gly
|
Thr57Ser;
Ser80Arg
|
Ser458Pro
|
A19
|
P, E
|
2000
|
ApCmCnNSxtTc
|
1,024
|
512
|
32
|
8
|
Ser83Phe;
Asp87Gly
|
Thr57Ser;
Ser80Arg
|
Ser458Pro
|
A20
|
P, E
|
2000
|
ApCmNSxtTc
|
2,048
|
512
|
32
|
8
|
Ser83Phe;
Asp87Gly
|
Thr57Ser;
Ser80Arg
|
Ser458Pro
|
A29
|
B, S
|
2000
|
CmNSxtTc
|
1,024
|
512
|
32
|
8
|
Ser83Phe;
Asp87Gly
|
Thr57Ser;
Ser80Arg
|
Ser458Pro
|
A36
|
B, S
|
2000
|
ApCmSxtTc
|
1,024
|
512
|
32
|
8
|
Ser83Phe;
Asp87Gly
|
Thr57Ser;
Ser80Arg
|
Ser458Pro
|
A41
|
P, S
|
2000
|
ApCmCnNSxtTc
|
1,024
|
512
|
32
|
16
|
Ser83Phe;
Asp87Gly
|
Thr57Ser;
Ser80Arg
|
Ser458Pro
|
A45
|
P, S
|
2000
|
ApCmNSxtTc
|
1,024
|
512
|
32
|
16
|
Ser83Phe;
Asp87Gly
|
Thr57Ser;
Ser80Arg
|
A51
|
P, S
|
2000
|
ApCmCnNSxtTc
|
1,024
|
512
|
16
|
4
|
Ser83Phe;
Asp87Gly
|
Thr57Ser;
Ser80Arg
|
A56
|
B, M
|
2000
|
ApCmCnNSxtTc
|
2,048
|
512
|
64
|
16
|
Ser83Phe;
Asp87Gly
|
Thr57Ser;
Ser80Arg
|
A61
|
P, S
|
2000
|
CmSxtTc
|
1,024
|
512
|
32
|
8
|
Ser83Phe;
Asp87Gly
|
Thr57Ser;
Ser80Arg
|
Ser458Pro
|
A62
|
P, S
|
2000
|
ApCmCnSxtTc
|
2,048
|
512
|
64
|
16
|
Ser83Phe;
Asp87Gly
|
Thr57Ser;
Ser80Arg
|
B16
|
P, E
|
2001
|
ApCmCnCroTc
|
2,048
|
512
|
32
|
16
|
Ser83Phe;
Asp87Gly
|
Thr57Ser;
Ser80Arg
|
Ser458Pro
|
B73
|
P, N
|
2003
|
ApCmCnNSxtTc
|
2,048
|
512
|
32
|
16
|
Ser83Phe;
Asp87Gly
|
Thr57Ser;
Ser80Arg
|
Ser458Pro
|
|
*QRDR, quinolone resistance–determining region;
B, broiler; M, middle Taiwan; P, pork; E, east Taiwan; S, south
Taiwan; N, north Taiwan.
|
†Antimicrobial agents are ampicillin (Ap), chloramphenicol
(Cm), ciprofloxacin (CIP), enrofloxacin (ENR), flumequine (FLU),
gentamicin (Cn), ceftriaxone (Cro), nalidixic acid (NAL),neomycin
(N), trimethoprim/sulfamethoxazole (Sxt), and tetracycline (Tc).
|
‡No gyrB substitutions were detected.
|
Suggested citation
for this article:
Wang Y-C, Yeh K-S,
Chang C-C, Hsuan S-L, Chen T-H. Fluoroquinolone-resistant Salmonella
sp. in carcasses [letter]. Emerg Infect Dis [serial on the Internet].
2006 Feb [date cited]. Available from http://www.cdc.gov/ncidod/EID/vol12no02/05-0629.htm
|